Impact
Impact
IFFIm's contributions have made it possible for Gavi to immunise more children, faster.
Since 2006, IFFIm has contributed US$ 5.8 billion to support Gavi’s vaccination programmes. This represents 18% of Gavi's overall funding1.
IFFIm funding has played a role in Gavi’s success in protecting children from infectious diseases so they can survive and thrive. Since 2000, Gavi has immunised one billion children and prevented more than 17 million deaths, helping to cut child mortality in half in 73 lower-income countries.
IFFIm accelerates Gavi’s impact. For example, Gavi was able to immunise nearly 100 million children ahead of receiving donor funding thanks to frontloading the proceeds of its signature impact investment, vaccine bonds.
In addition to financing for routine immunisation programmes, IFFIm funding also supports health system strengthening in lower-income countries and investment cases such as the COVAX AMC.
1 Percentage of Gavi funding from IFFIm from 2006 to 2023.
Addressing the COVID-19 pandemic
COVID-19 has created an urgent need for resources on a massive scale. As Gavi’s long-term, predictable and flexible funding source, IFFIm serves as a vehicle through which donors can support the Gavi COVAX AMC. Through IFFIm vaccine bonds, donors can accelerate funding to the COVAX AMC and help enable equitable access to these vaccines. IFFIm Vaccine Bonds have already generated US$ 975 million for Gavi to apply to the COVAX AMC for fair, global access to COVID-19 vaccines.
Read moreEradicating polio
IFFIm has played a critical role in the fight to end polio by providing funding that has helped slash incidence of the disease. IFFIm disbursed US$ 260 million to Gavi for polio programmes, including polio eradication and the inactivated polio vaccine, from 2006 to March 2022. When the Global Polio Eradication Initiative (GPEI) faced a crisis in 2006, it turned to IFFIm as the only way to finance stockpiling the polio vaccine so suppliers have it available for outbreaks. IFFIm invested US$191.28 million to help develop and license oral polio vaccine (OPV) products that could be field tested for safety and purchased in bulk. IFFIm’s support contributed to a striking 95% decline in polio cases in Nigeria and India, and an 85% decline in type 3 polio cases globally.
Read moreSuccess Stories
Learn how IFFIm funds have created a financial lifeline stretching from savvy and socially responsible donors and private investors to the world’s poorest communities.
Rotavirus vaccines return to an outbreak-hit county in Kenya
Supply chain disruption triggered a season of vaccine stockouts and sickness in Nakuru county. Now, health workers and parents are rushing to get their vulnerable babies protected.
How Uzbekistan scrambled to stay polio-free - and succeeded
Still endemic to neighbouring Afghanistan, polio was suddenly resurging in next-door Tajikistan. Uzbekistan’s health system needed to act fast, or risk the futures of its children.
How has IFFIm made a difference for Gavi?
Since 2006, IFFIm has contributed approximately US$ 5.2 billion to Gavi. IFFIm support has meant Gavi has been able to provide more life-saving vaccines, faster.
IFFIm funding contributes to health gains across Africa
IFFIm provides funding for 15% of Gavi’s immunisation programmes across Africa.
A new vaccine against typhoid rolls out in a flood-devastated province of Pakistan
Armed with vials of Typhoid Conjugate Vaccine, health workers in Balochistan are doing what they can to protect children threatened by a pincer movement of global crises: antimicrobial resistance on the one hand and climate change on the other.
Local solutions to local problems: Reaching zero-dose children in Chad’s nomadic communities
An innovative approach that combines children and animal vaccinations is helping to boost coverage amongst zero-dose children in Chad’s nomadic communities.
Dealing with diarrhoea: Nigeria introduces rotavirus vaccine into its immunisation plan
Nigeria has the second highest number of rotavirus deaths in the world. The historic introduction of the vaccine into its routine immunisation system aims to change that.
Kenya pushes back yellow fever outbreak while diagnostic capacity improves outcomes across Africa
Yellow fever cases are on the rise again, driven by an interruption in vaccinations during the COVID-19 pandemic.
COVAX on the move
Over the past year the Gavi COVAX AMC has been able to deliver 1.4 billion doses of life-saving jabs to 145 countries.
Restricted Access Library
The material in this Restricted Access Library is intended to be accessed only by persons with residence within the territory of a Member State of the European Union and is not intended to be viewed by any other persons. The material in this Restricted Access Library is provided by IFFIm for information purposes only and the materials contained herein were accurate only as of their respective dates. Certain information in the materials contained herein is not intended to be, and is not, current. IFFIm accepts no obligation to update any material contained herein.
Persons with residence outside the territory of a Member State of the European Union who have access to or consult any materials posted in this Restricted Access Library should refrain from any action in respect of the securities referred to in such materials and are otherwise required to comply with all applicable laws and regulations in their country of residence.
By clicking Access restricted content: DYNAMIC-LINK-TEXT I confirm that I have read and understood the foregoing and agree that I will be bound by the restrictions and conditions set forth on this page.
The materials in this Restricted Access Library are for distribution only to persons who are not a "retail client" within the meaning of section 761G of the Corporations Act 2001 of Australia and are also sophisticated investors, professional investors or other investors in respect of whom disclosure is not required under Part 6D.2 of the Corporations Act 2001 of Australia and, in all cases, in such circumstances as may be permitted by applicable law in any jurisdiction in which an investor may be located.
The materials in this Restricted Access Library and any documents linked from it are not for access or distribution in any jurisdiction where such access or distribution would be illegal. All of the securities referred to in this Restricted Access Library and in the linked documents have been sold and delivered. The information contained herein and therein does not constitute an offer for sale in the United States or in any other country. The securities described herein and therein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable state securities laws.
Each person accessing the Restricted Access Library confirms that they are a person who is entitled to do so under all applicable laws, regulations and directives in all applicable jurisdictions. Neither IFFIm nor any of their directors, employees, agents or advisers accepts any liability whatsoever for any loss (including, without limitation, any liability arising from any fault or negligence on the part of IFFIm or its respective directors, employees, agents or advisers) arising from access to Restricted Access Library by any person not entitled to do so.